Concourse Financial Group Securities, Inc. Immunity Bio, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$3.32 - $6.7 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$4.82 - $9.15 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$3.23 - $6.17 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.25 - $5.21 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.29 - $3.1 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.29 - $3.1 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.53 - $6.41 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.35 - $4.78 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$4.35 - $6.77 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$3.65 - $6.43 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.68 - $6.14 $0 - $0
Q1 2022 May 09, 2022	BUY	$5.05 - $7.53 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.67 - $10.18 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$9.17 - $14.24 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$13.41 - $22.4 $0 - $0
Q1 2021 May 13, 2021	BUY	$12.83 - $42.25 $0 - $0

Others Institutions Holding IBRX

# of Institutions

213

Shares Held

63.3M

Call Options Held

1.44M

Put Options Held

3.84M

Vanguard Group Inc Valley Forge, PA

13.8M
Shares

$73.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$60.5 Million
0.0% of portfolio
State Street Corp Boston, MA

7.86M
Shares

$41.7 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

3.92M
Shares

$20.8 Million
0.0% of portfolio
Jane Street Group, LLC New York, NY

1.72M
Shares

$9.1 Million
0.01% of portfolio

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $2.12B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account